Table 3.

Neutralizing synergy of p11D7 with plant‐made tixagevimab and cilgavimab at IC₂₅ concentrations against the B.1.1.529 variant

mAb Combination	Observed Neutralization (%)	HSA Predicted Neutralization (%)	Loewe Predicted Neutralization (%)
p11D7 + tixagevimab	43.96 ± 9.59	18.84 ± 3.96	26.08 ± 4.84
p11D7 + cilgavimab	34.76 ± 27.73	29.18 ± 14.99	48.90 ± 1.98
tixagevimab + cilgavimab	65.03 ± 2.62	35.14 ± 9.02	38.33 ± 7.02
p11D7 + tixagevimab + cilgavimab	93.92 ± 1.88	35.14 ± 9.02	50.45 ± 7.46

FFA data for each individual and combination of mAbs were performed at the IC₂₅ and per cent neutralization was analysed with the highest single agent (HSA) and Loewe models in SynergyFinder.org. Predicted values represent the expected per cent neutralization if no synergy between mAbs was occurring, while the observed per cent neutralization was the empirically determined value of the combination at the IC₂₅. An observed value higher than a predicted value is inferred to have synergetic interaction. At least two independent experiments with technical triplets were performed with SD values presented.